surpris move capit market via
leerink deal mark first foray capit market
without risk announc acquisit boston-bas
leerink partner cash plu retent payout
yr leerink full servic healthcar life science-
focus invest bank advisori capit market debt
equiti asset manag busi acquisit alreadi
approv leerink board expect close
bottom line surpris move one without risk
given bank first foray capit market busi
management previous less interest addit deal
come perceiv later stage cycl
also carri extend tbv earnback modest ep
accret said acknowledg synergi may exist
combin merit long-term play
life science/healthcar space lastli favor management willing
return excess capit via buyback also announc deal
ep estim move modestli deal accret
remain share transact like impact
earn visibl near term underli earn
impact elev franchis invest shift b/ trend
impli ltm revenu ltm earn absenc
meaning deal comp view deal valuat reason
rel publicli trade boutiqu invest bank ltm
earn indic leerink manag remain
place leerink oper svb leerink subsidiari
lastli full term retent payout
disclos key employe sign employ retent
agreement portion retent form
modestli accret indic acquisit expect
modestli accret ep specif
ep accret assum cost save inclus
intang amort acquisit expect irr
increas sivb rotc bp decreas
tce/ta bp decreas bp leerink trail
month revenu fee total expens
impli effici ratio management indic leerink
year averag annual revenu lastli
addit leerink sivb fee contribut increas
sizabl tbv earnback period static basi less via
crossov indic deal expect dilut
tbv crossov method earnback year
importantli management indic financi metric exclud revenu
synergi assum cost save post-clos includ modest
amount revenu synergi management indic earnback
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
like year said static basi tbv dilut divid
annual ep accret estim tbv earnback year
take long view cite attract healthcar space
rational behind deal management view capit market
cycl healthcar far cite year
run space addit bake sivb deal
metric management indic addit leerink better posit svb
attract larger corpor client within capit market also
borrow depositor management cite potenti continu
strong life science/healthcar loan growth go forward allud
potenti increas contribut lend time
current total loan lastli management cite potenti revenu
synergi privat bank wealth management
addit acquisit road management
indic focus integr leerink sivb
busi time said management impli addit
non-bank acquisit like line possibl expans
leerink platform key vertic
leerink
announc announc board director approv
share repurchas program expir
management indic sivb strong capit posit current cet
growth
opportun leerink invest return
capit sharehold stand-alone basi assum full
buy-back complet estim share
repurchas program would result ep benefit annual management
indic full buy-back would reduc bp
addit bp impact acquisit also management note
assum share repurchas complet
deal close tier leverag ratio would still within
rais ep est rais ep est
reflect impact
acquisit new buy-back program thru
despit upward ep revis lower tp
impli ep vs prior
compani
continu
provis loan loss
return average asset core
figur svb incom statement million
provis loan loss
gain deriv instrument client
compens benefit
furnitur equip
busi develop travel
minor interest net gain loss
earn tax core
earn tax report
provis tax core
provis tax report
figur svb financi balanc sheet million
due bank
fed fund repo
consum
total liabil equiti
price impli ep
wors expect credit trend slow loan growth pressur deposit cost interest rate hike develop slower
anticip market downturn technology/healthcar sector could pose downsid risk convers could
articl articl
time dissemin novemb
analyst john pancari rahul patil samuel ross primarili respons prepar research report attest follow
view opinion render research report reflect person view subject compani issuer
part research analyst compens directli relat specif recommend view research report
